Close

Trending

Measuring the cost-effectiveness of vaccines targeting infectious diseases

Could your loyalty card help spot cancer? Study says yes

JP Morgan 2023 – Adi Hoess

Tackling ongoing staffing burnout rates through AI-enabled precision oncology

Ipsen’s rare disease drug palovarotene knocked back in EU

Regenerative medicine

iPSC Pharma Phorum banner (1422 × 800 px)

Market Access/ Partner content/ Press releases

2nd iPSC-Derived Cell Therapies Summit

jade faulkner Allogenic, cell therapy, iPSC, Regenerative medicine, stem cell 0 Comment

The Industry’s Largest Event Showcasing iPSC Therapies

X

2nd iPSC-Derived Cell Therapies Summit

https://pharmaphorum.com/partner-content/2nd-ipsc-derived-cell-therapies-summit/

Mogrify-Leadership-Team-600x400

News/ News/ R&D

Astellas teams up with UK biotech Mogrify on hearing loss project

Phil Taylor Astellas, cell therapy, hearing loss, Mogrify, otology, partnering, Regenerative medicine 0 Comment

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy

X

Astellas teams up with UK biotech Mogrify on hearing loss project

https://pharmaphorum.com/news/astellas-teams-up-with-uk-biotech-mogrify-on-hearing-loss-project/

pharmaphorum_podcast-Episode-38

Podcast/ R&D/ Video/ Views & Analysis/ Views and analysis

Organicell on regenerative medicine: the pharmaphorum podcast

Dominic Tyer COVID-19, Dr Maria Ines Mitrani, Organicell Regenerative Medicine, podcast, Regenerative medicine 0 Comment

In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer

X

Organicell on regenerative medicine: the pharmaphorum podcast

https://pharmaphorum.com/r-d/regenerative-medicine-and-covid/

Danish pharma company Novo Nordisk

News/ News/ R&D

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

Phil Taylor cardiology, heart failure, Heartseed, Japan, Novo Nordisk, Regenerative medicine, stem cell therapy 0 Comment

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed

X

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

https://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/

vertex

News/ News/ R&D

FDA fast tracks type 1 diabetes cell therapy from Vertex

Phil Taylor cell therapy, fda, FDA fast track, Regenerative medicine, type 1 diabetes, Vertex Pharma 0 Comment

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and

X

FDA fast tracks type 1 diabetes cell therapy from Vertex

https://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/

Posting 1

Events/ Events/ Healthcare

2nd International Translational and Regenerative Medicine Conference

itmc@madridge.com Drug Discovery & Development, Novartis, Regenerative medicine, Stem cell research, Translational Research

ITMC-2019 Conference Valencia, Spain

X

2nd International Translational and Regenerative Medicine Conference

https://pharmaphorum.com/events/international-translational-regenerative-medicine-conference/

Max Salick, Novartis Institutes for Biomedical Research

Partner content/ Press releases/ R&D

Uncovering the biology of diseases in 3D

Teri Arri 3D Cell Culture, bioimaging, bioprinting, CRISPR, Regenerative medicine 0 Comment

Max Salick keynote address

X

Uncovering the biology of diseases in 3D

https://pharmaphorum.com/partner-content/uncovering-the-biology-of-diseases-in-3d/

Plasticell Banner 570x320

Articles/ Deep Dive/ R&D/ Views and analysis

Highs and lows in regenerative medicine

Linda Banks Deep Dive, Regenerative medicine, stem cell 0 Comment

How developments in gene editing and screening technology are advancing regenerative medicine.

X

Highs and lows in regenerative medicine

https://pharmaphorum.com/views-and-analysis/highs-lows-regenerative-medicine/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com